Loading
STAT3 (Signal transducer and activator of transcription 3) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Skin cancer and 5 more.
Signal transducer and transcription activator that mediates cellular responses to interleukins, KITLG/SCF, LEP and other growth factors. Once activated, recruits coactivators, such as NCOA1 or MED1, to the promoter region of the target gene. May mediate cellular responses to activated FGFR1, FGFR2, FGFR3 and FGFR4.
CIViC holds 2 clinical evidence items and 0 assertions across 4 variants. Open Targets scores its association with cancer at 0.78 (direct and indirect evidence; datatypes clinical 0.19, affected pathway 0.84, literature 1.00, genetic association 0.15, somatic mutation 0.97). IntOGen calls it a driver in 7 cohorts (7 activating, 0 loss-of-function), covering Diffuse Large B-Cell Lymphoma, NOS, Lymphoid Neoplasm, Malignant Lymphoma, Non-Hodgkin Lymphoma.
In plain words · STAT3 (Signal transducer and activator of transcription 3) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Skin cancer and 5 more.
STAT3 (Signal transducer and activator of transcription 3) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Skin cancer and 5 more.
Signal transducer and transcription activator that mediates cellular responses to interleukins, KITLG/SCF, LEP and other growth factors.
1 product aims at STAT3: small molecules. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
Immune or microenvironment target: its medicines act on immune, stromal or bone cells rather than on the tumour cell (drug mechanisms in the corpus). HPA STAT3: RNA low tissue specificity; high antibody staining in 2 normal tissues. Distribution: 6 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Lymphoma, Leukaemia, Skin cancer (all types), Lung cancer (all types), Ovarian cancer, Biliary tract cancer (all types)); Open Targets associates it with 1 specific cancer type at or above 0.5 (STAT3-related early-onset multisystem autoimmune disease). (Rule 1 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas STAT3 tissue; UniProt P40763; Open Targets ENSG00000168610 associations
First described 1994. Earliest sequence paper UniProt cites for the protein: Akira et al, Cell, 1994, "Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway". Source.
Sources: HGNC HGNC:11364 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P40763 (protein name, function text, keywords and locations (REST API)); CIViC gene STAT3 (2 evidence items, 0 assertions, 4 variants; diseases: Diffuse Large B-cell Lymphoma, T-cell Large Granular Lymphocyte Leukaemia (GraphQL API, CC0)); Open Targets ENSG00000168610 (association with cancer (MONDO_0004992) 0.78; per-cancer scores at or above 0.5: ovarian cancer 0.52, acute lymphoblastic leukaemia 0.51, diffuse large B-cell lymphoma 0.54, non-Hodgkin lymphoma 0.75, skin cancer 0.57, lung cancer 0.57 (GraphQL API, CC0)); IntOGen STAT3 (driver in 7 cohorts (Act 7, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Signal transducer and transcription activator that mediates cellular responses to interleukins, KITLG/SCF, LEP and other growth factors. Once activated, recruits coactivators, such as NCOA1 or MED1, to the promoter region of the target gene. May mediate cellular responses to activated FGFR1, FGFR2, FGFR3 and FGFR4. Upon activation of IL6ST/gp130 signalling by interleukin-6 (IL6), binds to the IL6-responsive elements identified in the promoters of various acute-phase protein genes. Activated by IL31 through IL31RA. Acts as a regulator of inflammatory response by regulating differentiation of naive CD4(+) T-cells into T-helper Th17 or regulatory T-cells (Treg): acetylation promotes its transcription activity and cell differentiation while deacetylation and oxidation of lysine residues by LOXL3 inhibits differentiation. Location: Cytoplasm; Nucleus (UniProt). Locus 17q21.2 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Adipose tissue, Adrenal gland, Appendix, Breast, Bronchus, Cerebellum, Cerebral cortex, Cervix.
No cancer stained high; medium in breast cancer, carcinoid, cervical cancer, colorectal cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Napabucasin, an oral drug marketed as a cancer stemness inhibitor, was tested in 1,134 people with untreated metastatic pancreatic cancer on top of nab-paclitaxel and gemcitabine; survival was identical and the trial was stopped for futility.
Query for this target: (TITLE:"STAT3" OR ABSTRACT:"STAT3" OR TITLE:"signal transducer and activator of transcription 3" OR ABSTRACT:"signal transducer and activator of transcription 3" OR TITLE:"Signal transducer and activator of transcription 3" OR ABSTRACT:"Signal transducer and activator of transcription 3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about STAT3, not a curated reading list.
Shares JAK-STAT signalling, Sezary syndrome, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma).
Shares Inflammation & NF-κB, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Leukaemia (all types), Skin cancer (all types).
Shares Leukaemia (all types), Skin cancer (all types), Acute lymphoblastic leukaemia, CIViC.
Shares Leukaemia (all types), Skin cancer (all types), Acute lymphoblastic leukaemia, CIViC.
Shares Inflammation & NF-κB, Leukaemia (all types), Skin cancer (all types), CIViC.
Shares JAK-STAT signalling, Hodgkin lymphoma, Skin cancer (all types), CIViC.
Shares Leukaemia (all types), Skin cancer (all types), Acute lymphoblastic leukaemia, CIViC.
Shares JAK-STAT signalling, Hodgkin lymphoma, CIViC, IntOGen.